Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF-C


Brief Information

Name:Vascular endothelial growth factor C
Target Synonym:LMPHM4,Vascular Endothelial Growth Factor-Related Protein,Flt4-L,VRP,FLT4 Ligand DHM,LMPH1D,VEGF-C,Vascular Endothelial Growth Factor C,Flt4 ligand,VEGFC
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
VEC-H52H3 Human Human VEGF-C / Flt4-L Protein, His Tag (MALS verified)
ACRO Quality

Part of Bioactivity data


Human VEGF-C Protein, His Tag (Cat. No. VEC-H52H3) capture on NTA-Series S sensor chip can bind  Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) with an affinity constant of 0.130 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

VEGF-C MALS images

The purity of Human VEGF-C Protein, His Tag (Cat. No. VEC-H52H3) is more than 90% and the molecular weight of this protein is around 30-45 kDa verified by SEC-MALS.

Synonym Name



Vascular endothelial growth factor C is also known as VEGFC, Flt4-L and VRP, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis, lymphangiogenesis and endothelial cell growth and survival, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor D (VEGF-D). VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Overexpression of VEGF-C causes lymphatics to enlarge possibly facilitates metastasis.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Sozinibercept OPT-302; VGX-300 Phase 3 Clinical Orphan Europe Sarl Neovascularization, Pathologic; Retinal Diseases; Diabetic macular oedema; Retinal Degeneration; Eye Diseases; Macular Degeneration Details
VEGF-C gene therapy (Herantis Pharma) LX-1101; Ad-VEGF-C Phase 2 Clinical Herantis Pharma Lymphedema Details
IBI-333 IBI-333 Phase 1 Clinical Innovent Biologics (Usa), Inc Wet Macular Degeneration; Macular Degeneration Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message